Everforth Inc annual report, FY2014

Business context and reporting period

This is On Assignment, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, with unaudited fourth-quarter results also included. The filing identifies the registrant as On Assignment, Inc. (NYSE: ASGN); it does not identify Everforth Inc. as the filer. The company provides contract, contract-to-hire, and direct-hire staffing, primarily in IT, engineering, and life sciences.

At year-end, the company reported four segments: Apex, Oxford, Physician, and Life Sciences Europe. Apex generated 64.0% of revenue, Oxford 26.5%, Physician 7.3%, and Life Sciences Europe 2.2%. In February 2015, the company completed the sale of its Physician segment.

Financial performance and liquidity

MetricFY 2014FY 2013
Revenue$1.860 billion$1.629 billion
Gross profit / margin$597.9 million / 32.1%$485.5 million / 29.8%
Operating income$146.3 million$124.4 million
Income from continuing operations$79.0 million$54.7 million
Net income$77.2 million$84.5 million
Diluted EPS, continuing operations / total$1.46 / $1.42$1.00 / $1.55
Operating cash flow$96.0 million$110.5 million

Revenue increased 14.2% reported and 8.5% on a pro forma basis assuming the 2013 acquisitions had occurred earlier. Management attributed growth to 8.2% organic growth and $104.4 million of revenue from CyberCoders and Whitaker. Gross margin improved mainly due to a higher share of direct-hire and conversion fees, particularly from CyberCoders. SG&A rose to $427.2 million, or 23.0% of revenue, from 20.8%, reflecting higher hiring and CyberCoders’ cost structure.

Fourth-quarter revenue was $475.8 million, versus $422.9 million in fourth-quarter 2013. Fourth-quarter income from continuing operations was $21.8 million, compared with $17.5 million.

At December 31, 2014, cash was $31.7 million, working capital was $220.3 million, and total debt was $415.1 million. The company had $45.8 million available under its revolving facility and reported compliance with debt covenants; its funded-debt-to-EBITDA leverage ratio was 2.06x. Net cash used in investing activities was $19.6 million, primarily reflecting $19.7 million of capital expenditures. Financing activities used $81.1 million, including $148.7 million in debt repayments and $100.0 million in share repurchases, partly offset by new borrowings.

Material changes, outlook, and risks

  • Net income declined from 2013, when it included a $30.8 million after-tax gain on the sale of Nurse Travel and Allied Healthcare. Continuing-operations income increased year over year.
  • In 2014, the company repurchased 3.4 million shares for $100.0 million at an average $29.78 per share. The board authorized another $100.0 million repurchase program in January 2015, effective February 23.
  • The Physician segment was sold effective February 1, 2015, for $123.0 million in cash. Its 2014 results remain in continuing operations in this filing; the company said it would present them as discontinued operations retrospectively in subsequent filings. A January 2015 credit amendment waived mandatory debt prepayment from this sale.
  • Management’s five-year strategic goal was to reach $3.0 billion in revenue by 2018 through organic growth and disciplined acquisitions. This is a strategic target, not a specific annual earnings or revenue forecast. Management estimated 2015 capital expenditures of approximately $19.0 million and expected available working capital, revolver capacity, and operating cash flows to fund needs over the next 12 months.
  • Key risks include cyclical staffing demand, competition and pricing pressure, retaining qualified professionals, execution and integration of acquisitions, legal and insurance exposures, healthcare-related regulation and costs, cybersecurity and information-system disruption, and debt covenants and interest-rate exposure. A 100-basis-point rate change on year-end variable-rate debt would change annual interest expense by approximately $4.2 million.
  • Goodwill was $570.7 million and identifiable intangible assets were $262.6 million. Annual impairment tests found no impairment, but management noted valuation sensitivity to forecasts and discount-rate assumptions. The company reported no legal matters expected to have a material financial effect and received unqualified audit opinions on its financial statements and internal controls.

Important facts for investors to verify

  • Review the Physician sale’s final proceeds, use of cash, and subsequent discontinued-operations presentation.
  • Track organic growth, segment-level bill rates and assignment volumes, and whether improved gross margins persist as hiring and SG&A costs rise.
  • Assess cash conversion and receivables: operating cash flow fell year over year while accounts receivable increased with business growth.
  • Monitor debt repayment, covenant headroom, variable-rate exposure, and the impact of repurchases on liquidity and leverage.
  • Evaluate whether the $3.0 billion 2018 revenue goal remains achievable and whether acquisitions or goodwill assumptions create additional execution or impairment risk.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.